Skip to main content
Pulmonary function in thalassaemia major and its correlation with body iron stores.
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes.
A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction.
Renal dysfunction in patients with thalassaemia.
Red cell alloimmunization in a diverse population of transfused patients with thalassaemia.
The effects of hydroxycarbamide and magnesium on haemoglobin SC disease: results of the multi-centre CHAMPS trial
Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload.
Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in North America.
Advances in clinical research in sickle cell disease.